Island Pharmaceuticals : Annual General Meeting MD Presentation

ersonal use only

MD PRESENTATION,

DR DAVID FOSTER, CEO & MD

DISCLAIMER

	This presentation has been prepared by Island Pharmaceuticals Limited	views on its future performance or condition. Actual results could differ	No representation, warranty or assurance (express or implied) is given
	(ABN 641 183 842) (Company or Island Pharmaceuticals).	materially from those referred to in this presentation. You should note	or made in relation to any forward-looking statement by any person
		that past performance of the Group is not and cannot be relied upon as	(including the Company). In particular, but without limitation, no
	Not an offer or financial product advice	an indicator of (and provides no guidance as to) future Group	representation, warranty or assurance (express or implied) is given that
	The Company is not licensed to provide financial product advice. This	performance.	the occurrence of the events expressed or implied in any forward
		looking statements in this presentation will actually occur. Actual
	presentation is not and should not be considered, and does not contain	Future performance	operations, results, performance or achievement may vary materially
	or purport to contain, an offer or an invitation to sell, or a solicitation of	This presentation contains certain "forward-looking statements". The	from any projections and forward-looking statements and the
	an offer to buy, directly or indirectly any securities, to any person in any	assumptions on which those statements are based. Any forward
	jurisdiction to whom or in which such offer or solicitation is unlawful	words "expect", "anticipate", "estimate", "intend", "believe", "guidance",	looking statements in this presentation speak only as of the date of this
	n r shall it (or any part of it), or the fact of its distribution, form the	"propose", "goals", "targets", "aims", "outlook", "forecasts", "should",	presentation.
	basis of, or be relied on in connection with or act as any inducement or	"could", "would", "may", "will", "predict", "plan" and other similar
onlyrec mmendation to enter into, any contract whatsoever relating to any	expressions are intended to identify forward-looking statements. Any	Subject to any continuing obligations under applicable law, the
	securities. This presentation is for information purposes only and is not	indications of, and guidance on, future operating performance,	Company disclaims any obligation or undertaking to provide any
	a prospectus, product disclosure statement, pathfinder document for	earnings and financial position and performance are also forward-	updates or revisions to any forward-looking statements in this
use	looking statements. Forward-looking statements in this presentation
	the purposes of section 734(9) of the Australian Corporations Act 2001	presentation to reflect any change in expectations in relation to any
	(Cth) (Corporations Act) or other offer document under Australian law	include statements regarding the Company's future growth options,	forward-looking statements or any change in events, conditions or
	or the law of any other jurisdiction. This presentation does not	strategies and new products. Forward-looking statements, opinions	circumstances on which any such statement is based.
	con titute an invitation to apply for or purchase Securities and does	and estimates provided in this presentation are based on assumptions
	not include any application form for Securities. This presentation does	and contingencies which are subject to change without notice, as are	Nothing in this presentation will under any circumstances create an
	not constitute an advertisement for an offer or proposed offer of	statements about market and industry trends, which are based on	implication that there has been no change in the affairs of the Group
	Sec rities. Neither this presentation nor anything contained in it shall	interpretations of current market conditions.	since the date of this presentation.
	form the basis of any contract or commitment and it is not intended to
	induce or solicit any person to engage in, or refrain from engaging in,	Forward-looking statements, including projections, guidance on future
	any transaction. Nothing in this presentation constitutes legal,	operations, earnings and estimates (if any), are provided as a general
ersonal	guide only and should not be relied upon as an indication or guarantee
	financial, tax or other advice. Recipients of the presentation should
	conduct their own investigation, evaluation and analysis of the	of future performance. No representation is given that the assumptions
	business and other data and information set out in the presentation.	upon which forward looking statements may be based are reasonable.
		This presentation contains statements that are subject to risk factors
	Fi ancial data All dollar values are in Australian dollars ($ or A$) unless	associated with the Group's industry. These forward-looking
	otherwise stated. Any financial data in this presentation is unaudited.	statements may be affected by a range of variables which could cause
	Past performance The operating and historical financial information	actual results or trends to differ materially, including but not limited to
	given in this presentation is given for illustrative purposes only and	earnings, capital expenditure, cash flow and capital structure risks and
	sh uld not be relied upon as (and is not) an indication of the Company's	general business risks.
ISLAND PHARMACEUTICALS LIMITED	2	AGM - NOVEMBER 2021

UPCOMING MILESTONES

only	H1 FY 2022
use	 Sign SUNY CTA
 Announce Principal
Investigator

• Engage CRO
• API manufacturing
• Advance research collaboration

ersonal

H2 FY 2022

• Complete clinical product
• File IND
• Open IND
• Screening subjects for PEACH* trial
• First subject in PEACH trial
• Advance through PEACH cohorts
• Screening libraries in research collaborations

H1 FY 2023

• Advance through PEACH cohorts
• Trial read out
• Meeting with FDA
• Identify lead molecules from research collaborations
• • PEACH: Phase 2a, randomized, double blind, placebo- controlled study for the Prophylactic Examination of an Antiviral in a Dengue Challenge Model.

ISLAND PHARMACEUTICALS LIMITED

3	AGM - NOVEMBER 2021

ISLAND AT A GLANCE

only	Island Pharmaceuticals (ASX: ILA) is a mid clinical-stage drug
repurposing company, focused on the rapid development of
			antiviral therapeutics for infectious diseases
use	Island	Island's drug	Initial focus is
repurposing
Pharmaceuticals	on mosquito
strategy
lists on the ASX	borne diseases
enables rapid
following	with a Phase II
and efficient
ersonal	oversubscribed	development	lead program
A$7.5m IPO in	in Dengue
of antiviral
April 2021	fever.
		therapies
ISLAND PHARMACEUTICALS LIMITED	4	AGM - NOVEMBER 2021

THE BENEFITS OF DRUG REPURPOSING

onlyuse

ersonalISLAND PHARMACEUTICALS LIMITED

5	AGM - NOVEMBER 2021